Able and willing to provide written informed consent and complete study assessments and follow-up.
Pre-COPD participants: age 35 years or older, without spirometric airflow obstruction, and with COPD risk factors and/or early clinical, pulmonary function, or imaging features according to the study protocol.
Stable COPD participants: age 40 years or older, with a diagnosis of COPD based on post-bronchodilator FEV1/FVC \< 0.70, in stable condition without acute exacerbation within the specified period before enrollment, and classified as GOLD stage 1-2 or GOLD stage 3-4.
Acute exacerbation of COPD participants: age 40 years or older, with COPD based on post-bronchodilator FEV1/FVC \< 0.70 and an acute exacerbation meeting protocol-defined criteria, enrolled within the protocol-defined time window.
Healthy control participants: age 35 years or older, without COPD based on symptoms, pulmonary function, and chest imaging criteria defined in the protocol.
Participants in COPD-related groups must have traditional Chinese medicine syndrome assessment information available according to the study protocol.
You may not be if
Unable or unwilling to provide informed consent or comply with study procedures and follow-up.
Respiratory diseases or other conditions that may substantially interfere with COPD-related assessments, including protocol-defined asthma, severe bronchiectasis, active pulmonary tuberculosis, lung cancer, interstitial lung disease, or other major pulmonary diseases.
Severe cardiovascular, hepatic, renal, hematologic, neurologic, psychiatric, malignant, immune, or infectious diseases that, in the investigator's judgment, make participation inappropriate or may affect study assessments.
Recent systemic glucocorticoid or antibiotic use, or other protocol-defined medication exposures, that may affect study-related sample collection or assessment.
Pregnancy or lactation, where applicable according to participant group.
Participation in another clinical study that may interfere with this study.
Any other condition judged by the investigator to make the participant unsuitable for this study.
Clareo Health | Multi-Omics Study of COPD Stages and Traditional Chinese Medicine Syndromes
